JPRN-UMIN000011971CompletedPhase 2
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group study - JALSG-STIM213 Study
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 62
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Patients with a history of treatment by the other TKI. 2)Patients with a history of hematopoietic stem cell transplantation. 3)Patients who have had blast crisis or accelerated CML. 4) Patients who have lost CMR during imatinib treatment. 5)Patients who have discontined imatinib treatment because of poor adherence. 6)Patients who do not want to re start imatinib after lost of MMR. 7)Other patients whom the investigator considers to be unsuitable for participation in the study.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatmentGastrointestinal stromal tumour (GIST)MedDRA version: 20.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003774-40-FIOslo University Hospital31
Recruiting
Phase 2
Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.JPRN-UMIN000012472Epidemiological and Clinical Research Information Network (ECRIN)100
Not yet recruiting
Not Applicable
To stop the use of Imatinib in CML-CP patientsCTRI/2019/07/020407DR BRA IRCH AIIMS
Completed
Phase 2
Discontinuation study of nilotinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop study in Japan adult leukemia study groupchronic myeloid leukemiaJPRN-UMIN000024985Japan Adult Leukemia Study Group51
Completed
Phase 2
Discontinuation study of nilotinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop study in Japan adult leukemia study groupchronic myeloid leukemiaJPRN-UMIN000024984Japan Adult Leukemia Study Group51